EMA Authorised: Piqray (alpelisib) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency authorised Piqray (alpelisib) by Novartis Europharm Limited for breast cancer, with decision dated 02 October 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Piqray (alpelisib)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Novartis Europharm Limited. Decision date: 02/10/2025